An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 125521
Company: ELI LILLY AND CO

Medication Guide

Summary Review

Products on BLA 125521

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
TALTZ	IXEKIZUMAB	80MG/ML	INJECTABLE;INJECTION	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 125521

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/22/2016	ORIG-1	Approval		N/A	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/125521Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/20/2023	SUPPL-31	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521Orig1s031lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/125521Orig1s031ltr.pdf
09/13/2023	SUPPL-28	Supplement	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/125521Orig1s028ltr.pdf
07/27/2022	SUPPL-24	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125521Orig1s024ltr.pdf
05/04/2022	SUPPL-23	Supplement		Label is not available on this site.
03/26/2020	SUPPL-20	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125521Orig1s020ltr.pdf
05/29/2020	SUPPL-19	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s019lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125521Orig1s019ltr.pdf
08/23/2019	SUPPL-16	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125521s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/125521Orig1s016ltr.pdf
03/10/2021	SUPPL-14	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125521Orig1s014ltr.pdf
03/16/2018	SUPPL-11	Supplement	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125521Orig1s011ltr.pdf
05/17/2018	SUPPL-9	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125521Orig1s009ltr.pdf
12/01/2017	SUPPL-4	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125521Orig1s004ltr.pdf
07/05/2017	SUPPL-3	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125521Orig1s003ltr.pdf
04/19/2018	SUPPL-2	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521Orig1s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125521Orig1s002ltr.pdf

Labels for BLA 125521

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/20/2023	SUPPL-31	Tentative Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521Orig1s031lbl.pdf
07/27/2022	SUPPL-24	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf
07/27/2022	SUPPL-24	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf
03/10/2021	SUPPL-14	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf
05/29/2020	SUPPL-19	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s019lbl.pdf
03/26/2020	SUPPL-20	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s020lbl.pdf
08/23/2019	SUPPL-16	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125521s016lbl.pdf
05/17/2018	SUPPL-9	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521s009lbl.pdf
04/19/2018	SUPPL-2		Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521Orig1s002lbl.pdf
12/01/2017	SUPPL-4	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf
07/05/2017	SUPPL-3	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s003lbl.pdf
03/22/2016	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf

Top